Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Дата публикации: 22-10-2026 22:12:19

Markers released top-line results today after previously reporting the trial succeeded.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Personalized cancer vaccine shows positive late-stage trial results	0	14.35	19-08-2026
2	Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test	0	6.58	19-08-2026
3	Interactive: A cancer vaccine is being tailored to individuals	0	12.1	19-08-2026
4	Kommentar: Modernas Studienerfolg ist ein Durchbruch im Kampf gegen Krebs	0	7.12	20-08-2026
5	mRNA 癌症疫苗将死亡复发风险减少 42%	0	20.18	23-10-2026
6	mRNA 癌症疫苗在 III 期黑色素瘤临床试验中取得积极成果	0	11.38	19-08-2026
7	Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success	0	7.16	15-10-2026
8	Moderna's cancer vaccine cuts melanoma recurrence risk in early trial: What we know	0	7.73	26-08-2026
9	MSD und Moderna: Positive Testergebnisse für Hautkrebs-mRNA-Impfstoff	0	19.04	20-08-2026
10	STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer	0	10.21	26-10-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.33. Источник: feeds.arstechnica.com.